Your browser doesn't support javascript.
loading
Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients.
Hong, Sukwoo; Garces, Yolanda I; Price, Katharine A; Shinya, Yuki; Parney, Ian F; Link, Michael J; Pollock, Bruce E.
Afiliação
  • Hong S; Department of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
  • Garces YI; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Price KA; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Shinya Y; Department of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
  • Parney IF; Department of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
  • Link MJ; Department of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA.
  • Pollock BE; Department of Neurological Surgery, Mayo Clinic, 200 First Street Southwest, 55905, Rochester, Minnesota, USA. Pollock.Bruce@mayo.edu.
J Neurooncol ; 166(2): 369-376, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38180687
ABSTRACT

PURPOSE:

This study aimed to analyze the treatment outcomes of single-fraction stereotactic radiosurgery (SRS) for adenoid cystic carcinoma patients.

METHODS:

Retrospective analysis was conducted for 55 patients with 66 lesions. SRS intentions were categorized as definitive, adjuvant, salvage, and palliative. Tumor control was defined as local (within 50% isodose line), marginal (outside 50% isodose line), and distant (metastasis outside head/neck).

RESULTS:

The median age was 60 years (range 21-85), with 53% males. Tumor origin was head/neck for 88% and trachea/lung for 12%. 61% were recurrent lesions. Median interval from diagnosis to SRS was 14 months. Preceding surgery was performed in 30%. SRS was administered as definitive (30 lesions), adjuvant (13), salvage (19), and palliative (4). SRS was used as a boost to external beam radiation therapy (EBRT) in 39%. Concurrent chemotherapy was administered in 26%. 5-, 10-, and 15-year local control rates were 60%, 33%, and 27%, respectively; local/marginal control rates were 29%, 13%, and 10%. For recurrent lesions treated with SRS without EBRT, 5-year local control rate was 14%, and local/marginal control rate was 5%. For recurrent lesions treated with SRS and EBRT, 5-year local control rate was 100%, and local/marginal control rate was 40%. The rate of distant failure after SRS was 40%. Older age and distant metastasis before SRS were negative factors for overall survival.

CONCLUSION:

SRS provided a high rate of local tumor control, but marginal failure was frequent. Integrating SRS with added EBRT exhibits potential for enhancing local and local/marginal tumor control, particularly in recurrent cases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Radiocirurgia / Carcinoma Adenoide Cístico Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Radiocirurgia / Carcinoma Adenoide Cístico Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article